Cue Biopharma Taps Veteran CMO to Steer High-Stakes Immunology Pipeline

BOSTON, MA – July 13, 2026

In a move signaling a concerted push to accelerate its clinical pipeline, Cue Biopharma has appointed veteran physician-scientist Dominic Borie, M.D., Ph.D., as its new Chief Medical Officer and Head of Research & Development. The appointment comes at a critical inflection point for the clinical-stage company, which is simultaneously preparing for a key data readout, launching a new trial, and operating with a freshly fortified balance sheet after a recent $50 million financing.

Dr. Borie, who reports directly to President and CEO Shao-Lee Lin, M.D., Ph.D., joins a leadership team in the midst of a strategic overhaul. His arrival is a clear indicator of Cue Biopharma's ambition to translate its complex immunology science into tangible therapies for patients with allergic and autoimmune diseases.

A Strategic Hire for a Critical Juncture

Dr. Borie is not just another executive appointment; his resume reads like a tour of immunology's most innovative frontiers. With over two decades of experience spanning biotech and global pharma giants, his expertise is tailor-made for Cue Biopharma's current challenges and opportunities. Most recently, he served as a strategic advisor at Kyverna Therapeutics, a company focused on cell therapies for autoimmune diseases, after a tenure as its founding CEO and President of R&D. This background is particularly relevant as Cue advances its own autoimmune candidate, CUE-401.

His track record includes senior leadership roles where he guided novel immunology programs from the lab to late-stage global studies. At Genentech, he was instrumental in securing new orphan disease indications for the blockbuster drug Rituxan®. His experience at Horizon Therapeutics, Amgen, and Roche further burnishes his credentials in inflammation and transplantation immunology—a field where he began his career as a transplant surgeon and academic researcher at Stanford University.

"Dr. Borie is an outstanding physician-scientist and clinical development leader whose experience spans discovery, development and advancement of innovative therapies for immune-mediated diseases," said CEO Shao-Lee Lin in a statement. "His deep expertise in immunology and proven leadership... will be invaluable as we advance our portfolio."

This expertise will be put to the test immediately. Cue Biopharma is navigating a high-stakes period, and Dr. Borie is tasked with steering the clinical strategy for its most promising assets. His appointment was accompanied by a significant inducement equity package, including options for 63,000 shares and 31,500 restricted stock units, a common but crucial tool in the biotech industry's intense "talent wars" to secure leaders capable of creating shareholder value.

Fortifying the Balance Sheet for Pipeline Acceleration

Talent alone doesn't fuel clinical trials; capital does. Alongside the leadership reinforcement, Cue Biopharma recently closed a $50 million private placement led by Cormorant Asset Management. This infusion of cash is not just welcome—it's vital.

A review of the company's public filings reveals the precarious financial tightrope clinical-stage biotechs often walk. Prior to this financing, the company's own reports contained a "going concern" warning, signaling substantial doubt about its ability to continue operations for the next twelve months without raising additional funds. With R&D expenses running at nearly $38 million last year against minimal revenue, the company was burning through its cash reserves.

The $50 million placement effectively addresses this near-term risk, extending the company’s operational runway. According to Dr. Lin, the new capital is sufficient to support the execution of upcoming clinical milestones for its two lead programs. This financial stability provides the necessary foundation for Dr. Borie and his team to execute their R&D plans without the immediate pressure of an empty treasury, a luxury in the current biotech funding environment.

Navigating a High-Stakes Clinical Gauntlet

With a seasoned leader at the helm and fresh capital in the bank, all eyes are now on Cue Biopharma's pipeline. The company's future hinges on two key assets, each with its own unique set of promises and risks.

First is CUE-221, a novel anti-IgE antibody for allergic diseases. The company expects a data readout from a Phase 2 trial in chronic spontaneous urticaria (CSU) by the end of the third quarter. This is a major catalyst, but one that comes with caveats. The trial is being conducted in China by a partner, Genesis Life Sciences, and Cue Biopharma does not hold the rights to the drug in that region. The applicability of this data to a global development strategy, which includes a planned Phase 2b trial in food allergy, remains a key question for investors and analysts.

The second major program is CUE-401, a wholly-owned asset emerging from the company's proprietary Immuno-STAT® platform. Described as a first-in-class bifunctional molecule combining IL-2 and TGF-β, it is designed to restore immune tolerance in autoimmune diseases. The company is on track to initiate a Phase 1 clinical trial by the end of the year. While the preclinical data is promising, CUE-401 is entering a notoriously difficult field. As a preclinical asset, it faces a high risk of failure, a reality underscored by reports that a clinically similar molecule from another company failed in later-stage trials. Dr. Borie’s experience in navigating the treacherous path from Phase 1 to approval will be paramount.

A New Era Under New Leadership

The appointment of Dr. Borie is the latest move in a strategic pivot that began in May with the hiring of Dr. Shao-Lee Lin as CEO. Together, they represent a new guard tasked with realizing the potential of Cue's science. The company has evolved from its initial focus on T-cell engagers for oncology to a broader immunology company, a strategy solidified by the in-licensing of CUE-221 for allergic diseases.

This revamped leadership team is now charged with executing a clear, if challenging, mission: advance CUE-221 based on the upcoming data and successfully bring CUE-401 into the clinic. Their ability to manage the associated risks, interpret complex clinical data, and articulate a coherent long-term vision to the market will determine whether Cue Biopharma can successfully transition from a company of scientific promise to one of therapeutic and commercial success. For now, the strategic pieces are in place, and the clock is ticking on the next clinical milestone.